Stock Track | Castle Biosciences Soars 6% as Leerink Partners Boosts Price Target

Stock Track

Nov 04, 2025

Castle Biosciences, Inc. (CSTL) stock is surging 6% in pre-market trading on Tuesday, following a positive analyst update. The movement comes after Leerink Partners raised its price target for the company from $35 to $40, signaling increased confidence in the stock's potential.

The upgrade from Leerink Partners suggests that analysts see improved prospects for Castle Biosciences, a company known for its innovative diagnostic and prognostic tests for dermatological cancers. This vote of confidence from a respected financial firm appears to be driving investor enthusiasm, resulting in the significant pre-market price increase.

While specific reasons for the target price increase were not provided in the available information, such upgrades are typically based on factors like improved financial performance, promising product developments, or positive industry trends. Investors are advised to monitor any forthcoming detailed reports from Leerink Partners for a more comprehensive understanding of the factors behind this bullish outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1105784475"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105784475\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105784475?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105784475","market":"hk","top_or_hot":-1,"title":"Stock Track | Castle Biosciences Soars 6% as Leerink Partners Boosts Price Target","media":"Stock Track","content":"<p>Castle Biosciences, Inc. (CSTL) stock is surging 6% in pre-market trading on Tuesday, following a positive analyst update. The movement comes after Leerink Partners raised its price target for the company from $35 to $40, signaling increased confidence in the stock's potential.</p>\n\n<p>The upgrade from Leerink Partners suggests that analysts see improved prospects for Castle Biosciences, a company known for its innovative diagnostic and prognostic tests for dermatological cancers. This vote of confidence from a respected financial firm appears to be driving investor enthusiasm, resulting in the significant pre-market price increase.</p>\n\n<p>While specific reasons for the target price increase were not provided in the available information, such upgrades are typically based on factors like improved financial performance, promising product developments, or positive industry trends. Investors are advised to monitor any forthcoming detailed reports from Leerink Partners for a more comprehensive understanding of the factors behind this bullish outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Castle Biosciences Soars 6% as Leerink Partners Boosts Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Castle Biosciences Soars 6% as Leerink Partners Boosts Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Castle Biosciences, Inc. (CSTL) stock is surging 6% in pre-market trading on Tuesday, following a positive analyst update. The movement comes after Leerink Partners raised its price target for the company from $35 to $40, signaling increased confidence in the stock's potential.</p>\n\n<p>The upgrade from Leerink Partners suggests that analysts see improved prospects for Castle Biosciences, a company known for its innovative diagnostic and prognostic tests for dermatological cancers. This vote of confidence from a respected financial firm appears to be driving investor enthusiasm, resulting in the significant pre-market price increase.</p>\n\n<p>While specific reasons for the target price increase were not provided in the available information, such upgrades are typically based on factors like improved financial performance, promising product developments, or positive industry trends. Investors are advised to monitor any forthcoming detailed reports from Leerink Partners for a more comprehensive understanding of the factors behind this bullish outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSTL","symbol_name":"Castle Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1105784475","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105784475","pubTimestamp":1762267842,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Castle Biosciences, Inc. (CSTL) stock is surging 6% in pre-market trading on Tuesday, following a positive analyst update. The movement comes after Leerink Partners raised its price target for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSTL":"Castle Biosciences, Inc."},"translate_title":"股票追踪|Leerink Partners上调目标价，Castle Biosciences股价飙升6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSTL":1},"content_text":"Castle Biosciences, Inc. (CSTL) stock is surging 6% in pre-market trading on Tuesday, following a positive analyst update. The movement comes after Leerink Partners raised its price target for the company from $35 to $40, signaling increased confidence in the stock's potential.\nThe upgrade from Leerink Partners suggests that analysts see improved prospects for Castle Biosciences, a company known for its innovative diagnostic and prognostic tests for dermatological cancers. This vote of confidence from a respected financial firm appears to be driving investor enthusiasm, resulting in the significant pre-market price increase.\nWhile specific reasons for the target price increase were not provided in the available information, such upgrades are typically based on factors like improved financial performance, promising product developments, or positive industry trends. Investors are advised to monitor any forthcoming detailed reports from Leerink Partners for a more comprehensive understanding of the factors behind this bullish outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}